Attached files
| file | filename |
|---|---|
| 10-Q - FORM 10-Q - Cascadian Therapeutics, Inc. | v57259e10vq.htm |
| EX-31.2 - EX-31.2 - Cascadian Therapeutics, Inc. | v57259exv31w2.htm |
| EX-31.1 - EX-31.1 - Cascadian Therapeutics, Inc. | v57259exv31w1.htm |
| EX-32.2 - EX-32.2 - Cascadian Therapeutics, Inc. | v57259exv32w2.htm |
| EX-32.1 - EX-32.1 - Cascadian Therapeutics, Inc. | v57259exv32w1.htm |
Exhibit 12.1
Oncothyreon Inc. and Consolidated Subsidiaries
Statement Regarding Computation of Ratio of Earnings to Fixed Charges
| For the Nine | ||||
| Months Ended | ||||
| September 30, | ||||
| 2009 | ||||
Earnings before fixed charges: |
||||
Income/(loss) from continuing operations before income taxes,
minority interest and income/(loss) from equity investees |
$ | (9,464 | ) | |
Add fixed charges |
21 | |||
Add amortization of capitalized interest |
— | |||
Add distributed income of equity investees |
— | |||
Subtract capitalized interest |
— | |||
Income/(loss) before fixed charges |
$ | (9,443 | ) | |
Fixed charges: |
||||
Interest expense |
$ | — | ||
Amortization of debt expense |
— | |||
Estimate of interest expense within rental expense |
21 | |||
Preference security dividend requirements of consolidated subsidiaries |
— | |||
Total fixed charges |
$ | 21 | ||
Deficiency of earnings available to cover fixed charges |
$ | (9,464 | ) | |